[Use of GnRH antagonists (cetrorelix) in assisted reproduction: first report in Mexican literature].

Kably Ambe A, Ruiz AJ, Baptista AA, Serulle Y, Quesnel BC

Ginecologia y obstetricia de Mexico1 Sept 2002Cited by 1 (Europe PMC)

PMID12448050PepBankPUB-12448050

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, oocyte retrieval, fertilization and implantation rates did not differ between cetrorelix and GnRH agonists.
In plain wordsIn IVF/ICSI patients, egg retrieval, fertilization and implantation rates did not differ between cetrorelix and GnRH agonists.
Peptide
Cetrorelix
Outcome
Direction not reportedOocyte retrieval, fertilization and implantation rates
Study
n: not reported in source
Comparator
GnRH agonists
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/day · subcutaneousAs given in this study (human).
Source sentences
Summary
No difference was observed in oocyte retrieval, fertilization rate, implantation rate between both groups (GnRH antagonists versus GnRH agonists).
1 context sentence(design, population, supporting numbers)
Summary · context
The present study reports the use of a GnRH antagonist (cetrorelix) 0.25 mg/d s.c. in patients stimulated with recombinant FSH (rFSH) for IVF/ICSI.
Report a problemFND-1244805006
02HumanNon-randomized trialEfficacy outcome
After successful embryo transfer, pregnancy occurred in 17 of 41 cetrorelix patients versus 8 of 20 GnRH agonist patients.
In plain wordsAfter successful transfer, pregnancy occurred in 17 of 41 cetrorelix patients versus 8 of 20 GnRH agonist patients.
Peptide
Cetrorelix
Outcome
Direction not reportedPregnancy after successful transfer
Study
n: not reported in source
Comparator
GnRH agonists
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/day · subcutaneousAs given in this study (human).
Measurements
Pregnancy after successful transfer
17 patients
cetrorelix group, of 41 patients with successful transfer
Pregnancy after successful transfer
8 patients
GnRH agonist group, of 20 patients
Source sentences
Summary
In 17 of 41 patients with successful transfer, pregnancy was achieved in the group with antagonists, and 8 of 20 patients in the group with agonists.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study reports the use of a GnRH antagonist (cetrorelix) 0.25 mg/d s.c. in patients stimulated with recombinant FSH (rFSH) for IVF/ICSI.
Report a problemFND-1244805007
03HumanObservational studyEfficacy outcome
In IVF/ICSI patients receiving cetrorelix, two patients had a premature LH surge above 10 UI/L.
In plain wordsAmong IVF/ICSI patients receiving cetrorelix, two had a premature LH surge above 10 UI/L.
Peptide
Cetrorelix
Outcome
Not applicablePremature LH surge
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/day · subcutaneousAs given in this study (human).
Measurements
Premature LH surge
2 patients
LH > 10 UI/L during ovarian stimulation
Source sentences
Summary
The LH serum concentrations were monitored during ovaric stimulation, in two patients a premature LH surge (> 10 UI/L) was detected.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study reports the use of a GnRH antagonist (cetrorelix) 0.25 mg/d s.c. in patients stimulated with recombinant FSH (rFSH) for IVF/ICSI.
Report a problemFND-1244805001
04HumanObservational studyEfficacy outcome
In IVF/ICSI patients receiving cetrorelix, mean preovulatory estradiol was 4.006 +/- 2.418 pg/mL.
In plain wordsIn IVF/ICSI patients receiving cetrorelix, mean preovulatory estradiol was 4.006 +/- 2.418 pg/mL.
Peptide
Cetrorelix
Outcome
Not applicablePreovulatory estradiol
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/day · subcutaneousAs given in this study (human).
Measurements
Mean preovulatory oestradiol
4.006 pg/mL
IVF/ICSI patients receiving cetrorelix
Preovulatory oestradiol, +/- value (spread type not stated)
2.418 pg/mL
IVF/ICSI patients receiving cetrorelix
Source sentences
Summary
The oocytes were collected 36 hours after hCG administration, the mean preovulatory oestradiol was 4.006 +/- 2.418 pg/mL.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study reports the use of a GnRH antagonist (cetrorelix) 0.25 mg/d s.c. in patients stimulated with recombinant FSH (rFSH) for IVF/ICSI.
Report a problemFND-1244805002
05HumanObservational studyEfficacy outcome
In IVF/ICSI patients receiving cetrorelix, mean oocyte retrieval was 10.8 +/- 7.4 per patient.
In plain wordsIn IVF/ICSI patients receiving cetrorelix, average egg retrieval was 10.8 +/- 7.4 per patient.
Peptide
Cetrorelix
Outcome
Not applicableOocytes retrieved
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/day · subcutaneousAs given in this study (human).
Measurements
Mean total oocytes retrieved
10.8 oocytes per patient
IVF/ICSI patients receiving cetrorelix
Oocytes retrieved, +/- value (spread type not stated)
7.4 oocytes per patient
IVF/ICSI patients receiving cetrorelix
Source sentences
Summary
The mean total oocytes retrieved was 10.8 +/- 7.4 per patient, the fertilization rate was 58.3%, in only three patients fertilization was failed.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study reports the use of a GnRH antagonist (cetrorelix) 0.25 mg/d s.c. in patients stimulated with recombinant FSH (rFSH) for IVF/ICSI.
Report a problemFND-1244805003
06HumanObservational studyEfficacy outcome
In IVF/ICSI patients receiving cetrorelix, the fertilization rate was 58.3%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix, the fertilization rate was 58.3%.
Peptide
Cetrorelix
Outcome
Not applicableFertilization rate
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/day · subcutaneousAs given in this study (human).
Measurements
Fertilization rate
58.3%
IVF/ICSI patients receiving cetrorelix
Source sentences
Summary
The mean total oocytes retrieved was 10.8 +/- 7.4 per patient, the fertilization rate was 58.3%, in only three patients fertilization was failed.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study reports the use of a GnRH antagonist (cetrorelix) 0.25 mg/d s.c. in patients stimulated with recombinant FSH (rFSH) for IVF/ICSI.
Report a problemFND-1244805004
07HumanObservational studyEfficacy outcome
In IVF/ICSI patients receiving cetrorelix, fertilization failed in three patients.
In plain wordsIn IVF/ICSI patients receiving cetrorelix, fertilization failed in three patients.
Peptide
Cetrorelix
Outcome
Not applicableFertilization failure
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/day · subcutaneousAs given in this study (human).
Measurements
Fertilization failure
3 patients
IVF/ICSI patients receiving cetrorelix
Source sentences
Summary
The mean total oocytes retrieved was 10.8 +/- 7.4 per patient, the fertilization rate was 58.3%, in only three patients fertilization was failed.
1 context sentence(design, population, supporting numbers)
Summary · context
The present study reports the use of a GnRH antagonist (cetrorelix) 0.25 mg/d s.c. in patients stimulated with recombinant FSH (rFSH) for IVF/ICSI.
Report a problemFND-1244805005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.